Nurix Therapeutics, Inc.: Form 10-Q for the period ended Aug 31, 2025
Filed with the SEC on Oct 9, 2025 and accepted by EDGAR at Oct 9, 2025, 16:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-08-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-06-01 to 2025-08-31 | $7.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2024-12-01 to 2025-08-31 | $70.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2025-06-01 to 2025-08-31 | $86.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2024-12-01 to 2025-08-31 | $233.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-06-01 to 2025-08-31 | −$91.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-12-01 to 2025-08-31 | −$202.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-06-01 to 2025-08-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-12-01 to 2025-08-31 | $760.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-06-01 to 2025-08-31 | −$86.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-12-01 to 2025-08-31 | −$186.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-06-01 to 2025-08-31 | −$1.03 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-12-01 to 2025-08-31 | −$2.22 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-06-01 to 2025-08-31 | −$1.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-12-01 to 2025-08-31 | −$2.22 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-06-01 to 2025-08-31 | 84,159,336 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-12-01 to 2025-08-31 | 83,869,469 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-12-01 to 2025-08-31 | −$181.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2024-12-01 to 2025-08-31 | $8.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-08-31 | $78.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-08-31 | $440.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-08-31 | $522.5m | us-gaap:Assets |
| Current liabilities | At period end2025-08-31 | $82.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-08-31 | $150.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-08-31 | $372.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001549595-25-000113. Last ingested by Listed: Nov 5, 2026, 13:59 ET. Listed shows no prices and gives no investment advice.